Carisma Therapeutics, Inc.

Equities

CARM

US14216R1014

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
2.27 USD +1.34% Intraday chart for Carisma Therapeutics, Inc. -9.56% -22.53%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Inflation Data -2- DJ
Carisma Therapeutics' First Lead Candidate Under Moderna Deal to Target Cancer Treatment MT
Carisma Therapeutics Obtains FDA Clearance to Study Potential Solid Tumor Therapy MT
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte CI
Carisma Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
North American Morning Briefing : Stocks Look to -2- DJ
Carisma Therapeutics Inc. Presents Pre-Clinical Proof of Concept for in vivo CAR-M Using mRNA Platform in Collaboration with Moderna at SITC CI
Carisma Therapeutics Inc. to Present First Results from in Vivo Car-M Collaboration with Moderna at SITC 2023 CI
Capital Starts Carisma Therapeutics at Overweight With $10 Price Target MT
Carisma Therapeutics, Inc. Announces Latest Data from Phase 1 Clinical Trial of CT-0508 At 8th Annual CAR-TCR Summit CI
HC Wainwright Adjusts Price Target on CARISMA Therapeutics to $11 From $10, Keeps Buy Rating MT
North American Morning Briefing : Investors Await -2- DJ
Evercore ISI Initiates CARISMA Therapeutics at Outperform With $12 Price Target MT
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with Keytruda(R) (Pembrolizumab) in Patients with Her2 Overexpressing Solid Tumors CI
Carisma Therapeutics Inc. Appoints Eric Siegel as General Counsel and Corporate Secretary and Terry Shields as Senior Vice President of Human Resources CI
HC Wainwright Starts Carisma Therapeutics at Buy With $10 Price Target MT
Carisma Therapeutics Inc. Provides Pipeline Updates CI
Carisma Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Carisma Therapeutics Files for Potential Follow-on, Secondary Offerings MT
Baird Initiates CARISMA Therapeutics at Outperform With $10 Price Target MT
Carisma Therapeutics, Inc.(NasdaqGM:CARM) added to NASDAQ Composite Index CI
Sesen Bio, Inc.(NasdaqCM:SESN) dropped from NASDAQ Composite Index CI
Carisma Therapeutics, Inc. announced that it has received $30 million in funding from a group of investors CI
CARISMA Therapeutics Inc. completed the acquisition of Sesen Bio, Inc. from The Vanguard Group, Inc., JEC II Associates, LLC, BML Investment Partners, L.P. managed by BML Capital Management, LLC and others in a reverse merger transaction. CI
Chart Carisma Therapeutics, Inc.
More charts
Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company's macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company's lead product candidate, CT-0508, is a Chimeric Antigen Receptor Macrophage (CAR-M) to be evaluated in a human clinical trial and is intended to treat solid tumors that overexpress HER2. The Company's second product candidate, CT-0525, is also intended to treat solid tumors that overexpress HER2, is in preclinical development. Beyond CT-0508 and CT-0525, the Company has a pipeline of cell therapy assets in various stages of pre-clinical development. The Company is also developing in vivo CAR-M gene therapies.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.27 USD
Average target price
9.5 USD
Spread / Average Target
+318.50%
Consensus
  1. Stock
  2. Equities
  3. Stock Carisma Therapeutics, Inc. - Nasdaq
  4. News Carisma Therapeutics, Inc.
  5. Sesen Bio to Merge With Carisma Therapeutics in All-Stock Deal